MedInCell Stock Drops 2% to €28.14 Despite Raised Target of €52 by Oddo
The Montpellier-based biotech's stock fell 2.02% to €28.14 at midday in a sluggish Paris market. The SBF 120 is down 1.36% in session and the CAC 40 has declined by 1.42%. However, the stock still maintains a gain of nearly 82% over the year and 6.8% over the week.
Oddo BHF Raises Target to €52, Evercore ISI Lowers Its to €36
Two analyst notes dated May 14 are stirring interest in MedInCell. Oddo BHF has raised its price target from €50 to €52, maintaining an outperform rating. Evercore ISI also maintains an outperform rating but has lowered its target from €43 to €36. Based on the midday price of €28.14, Oddo BHF's target implies a theoretical potential of about 85%, while Evercore ISI's target suggests a potential of about 28%. Both firms remain buyers despite diverging valuation trajectories. The market can view the detailed recommendations to understand these opinions within the consensus.
Stock Enters Overbought Territory at 94% of Upper Bollinger Band
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The session's decline comes after several days of acceleration. The price at €28.14 is positioned at the high end of the Bollinger Bands, at 94% of its upper limit set at €28.55. The RSI at 72 confirms an overbought configuration. The stock remains well above its 50-day moving average (€23.37, a 20.4% difference) and its 200-day average (€24.64, a 14.2% difference), reflecting the bullish trajectory of recent weeks. The technical resistance identified at €28.72 now limits the movement. For reference, the company's R&D day on May 11 supported the stock. The next calendar event is the 2026 general meeting, scheduled for September 10.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
